Peptide Drug-Device Combination Products: Trends Shaping the Future of Delivery

Peptide drugs do not work unless they get into the body the right way.

That is where drug-device combination products come in.

These products pair a peptide drug with a delivery device like an autoinjector, pen, or patch to make treatment easier and more reliable for patients.

The market for these combination products is growing fast, driven by the boom in peptide therapies.

What Are Drug-Device Combination Products?

A drug-device combination product is exactly what it sounds like. It combines a drug and a medical device into a single product.

For peptide therapies, the most common examples are:

• Prefilled syringes containing a peptide drug
• Autoinjector pens that patients use at home
• On-body injectors worn as patches
• Nasal spray devices for peptide delivery
• Implantable pumps that release peptides over time

The drug and the device are designed to work together. Neither one works properly without the other.

The FDA regulates these products under specific rules that cover both the drug and the device components.

Why Combination Products Matter for Peptides

Most peptides cannot be taken as a simple pill.

They break down in the stomach before they can work.

That means peptide drugs usually need to be injected, inhaled, or absorbed through the skin.

The delivery device determines how well the drug works and how willing patients are to use it.

A poorly designed device can lead to incorrect dosing, painful injections, or patients simply giving up on treatment.

A well-designed device makes treatment easy and consistent. Patients stick with their therapy longer, and outcomes improve.

"The device is not just packaging for the drug. It is a critical part of the therapeutic experience. When we get the device right, patient adherence goes up dramatically," says Dr. Laura Mendez, a drug delivery engineer.

Current Market Landscape

The drug-device combination product market is large and growing.

Metric	Value
Global market size (2025)	$162 billion
Projected market size (2030)	$245 billion
Peptide-specific share	18-22%
Growth rate (CAGR)	8.6%

Peptide therapies account for a significant share of this market because of the strong growth in GLP-1 receptor agonists, growth hormones, and other injectable peptides.

The explosive growth of GLP-1 peptide drugs for weight loss and diabetes has created significant demand for injection pen devices. Some manufacturers have reported 300 percent increases in device orders since 2023.

Types of Peptide Drug-Device Combination Products

Let us look at each type in more detail.

Prefilled Syringes

The simplest form of combination product. The peptide drug comes already loaded in a syringe.

Patients or healthcare providers just attach a needle and inject.

Prefilled syringes reduce dosing errors and contamination risk compared to drawing drug from a vial.

Autoinjector Pens

These are the workhorses of peptide delivery.

Patients dial their dose, place the pen against their skin, and press a button. The device does the rest.

Modern autoinjector pens include features like:

• Automatic needle insertion and retraction
• Dose memory that tracks the last injection
• Audible and visual confirmation of dose delivery
• Ergonomic design for patients with limited hand strength

Multi-Dose Pens

These pens hold enough drug for multiple injections. Patients use the same pen for days or weeks.

This is common for peptide therapies that require daily dosing, like certain growth hormone treatments.

Multi-dose pens need preservatives to keep the drug stable after the first use.

On-Body Injectors

These are wearable devices that stick to the skin and deliver the drug over minutes or hours.

They are ideal for peptide therapies that require larger volumes that cannot be injected all at once.

Patients apply the device, start the injection, and go about their day.

Smart Connected Devices

The newest generation of combination products includes digital connectivity.

Smart pens and injectors can:

• Track injection times and doses
• Send data to smartphone apps
• Remind patients when the next dose is due
• Share data with healthcare providers
• Detect missed doses or incorrect usage

This connectivity improves adherence and gives doctors better insight into how patients use their medications.

Regulatory Pathway for Combination Products

Combination products face a unique regulatory landscape.

The FDA's Office of Combination Products determines which FDA center reviews each product. The primary mode of action decides whether the drug center (CDER) or device center (CDRH) takes the lead.

For most peptide drug-device combinations, CDER leads the review because the drug is the primary mode of action.

Key regulatory requirements include:

• Demonstrating that the device delivers the drug accurately and consistently
• Human factors testing to prove patients can use the device safely
• Stability testing of the drug in the device over the product's shelf life
• Container closure integrity testing
• Device reliability and durability testing
• Labeling that covers both drug and device instructions

The regulatory process for combination products typically takes longer than for standalone drugs because of the additional device requirements.

Human Factors Engineering

Human factors testing is a critical part of combination product development.

It evaluates whether patients can use the device correctly without making errors that could harm them.

Testing involves watching real patients (or simulated patients) use the device and recording any difficulties or mistakes.

Common issues found during human factors testing include:

• Difficulty removing needle caps
• Confusion about dose setting
• Failure to hold the device against the skin long enough
• Problems reading dose indicators
• Difficulty with device disposal

Fixing these issues before launch prevents real-world problems.

Companies typically conduct formative studies during development and a summative (validation) study before filing for approval.

Manufacturing Challenges

Making combination products is more complex than making drugs or devices alone.

You need capabilities in both pharmaceutical manufacturing and device assembly.

Key manufacturing challenges include:

• Sterile filling of the drug into the device under GMP conditions
• Component sourcing for device parts from qualified suppliers
• Assembly and packaging that maintains sterility and device function
• Testing of both drug quality and device performance on every batch
• Cold chain management for temperature-sensitive peptide formulations in devices

Many peptide companies outsource device manufacturing to specialized contract manufacturers.

Others partner with device companies through co-development agreements.

For insights on managing peptide manufacturing partnerships, see our guide on peptide CMO selection criteria.

Patient Adherence and Outcomes

The whole point of a better delivery device is better patient outcomes.

Data consistently shows that well-designed combination products improve adherence.

Delivery Method	Typical Adherence Rate
Vial and syringe (manual)	50-60%
Prefilled syringe	60-70%
Autoinjector pen	70-80%
Smart connected device	80-90%

Higher adherence means patients get the full benefit of their peptide therapy.

This translates into better clinical outcomes, fewer hospitalizations, and lower total healthcare costs.

Emerging Technologies

Several new technologies are pushing the boundaries of peptide drug-device combination products.

Microneedle patches use tiny needles that painlessly deliver peptides through the skin. No injection fear, no sharps disposal.

Implantable devices release peptides slowly over weeks or months, eliminating the need for daily or weekly injections.

Inhalation devices deliver peptides through the lungs, bypassing the digestive system while avoiding needles.

3D-printed devices enable personalized device designs tailored to individual patient needs.

Closed-loop systems combine a peptide delivery device with a sensor that monitors the patient's condition and adjusts dosing automatically.

These technologies are at different stages of development, but some will reach the market within the next five years.

Intellectual Property Considerations

Combination products create complex IP situations.

Patents may cover the drug, the device, the formulation, the delivery mechanism, and the combination itself.

Companies need strong IP strategies to protect their investments.

They also need freedom-to-operate analyses to make sure they are not infringing on existing patents.

The combination of drug and device patents can extend market exclusivity beyond what either component would provide alone.

This makes combination products attractive from a business strategy perspective.

Workforce Needs

Developing combination products requires a diverse team.

You need:

• Formulation scientists who understand peptide stability in device systems
• Mechanical engineers who design device mechanisms
• Human factors specialists who test usability
• Regulatory experts who navigate combination product pathways
• Quality engineers who manage both drug and device quality systems
• Project managers who coordinate cross-functional development

Finding people with experience in both drugs and devices is challenging.

Many companies build teams by combining drug development veterans with device industry hires.

For more on building specialized teams, read our article on biotech talent acquisition strategy.

The average development timeline for a peptide drug-device combination product is 5 to 8 years from concept to market launch. Human factors testing and device design iterations are often the longest phases.

Looking Ahead

The future of peptide drug-device combination products is shaped by several clear trends:

• Smart connected devices will become standard for most new peptide therapies
• Microneedle patches will offer pain-free alternatives for some peptide drugs
• Platform device designs will reduce development time for new peptide formulations
• Sustainability-focused design will reduce device waste and environmental impact
• Patient-centric design will drive improvements in device ergonomics and usability

The combination of better peptide drugs and smarter delivery devices will improve treatment for millions of patients worldwide.

Frequently Asked Questions

What is a drug-device combination product?

A drug-device combination product pairs a medication with a delivery device, such as a peptide drug in an autoinjector pen. The drug and device are designed to work together as a single product.

Why do peptide drugs need delivery devices?

Most peptides cannot be taken orally because they break down in the stomach. Delivery devices like injector pens, patches, and inhalers get the peptide into the body effectively.

How does the FDA regulate combination products?

The FDA's Office of Combination Products assigns each product to a lead review center based on its primary mode of action. Most peptide combinations are reviewed by CDER with input from CDRH.

What is human factors testing?

Human factors testing evaluates whether patients can use a device safely and correctly. It involves watching people use the device and identifying any difficulties or errors.

How do smart connected devices improve treatment?

Smart devices track injection times and doses, send reminders, and share data with healthcare providers. This improves adherence and helps doctors make better treatment decisions.

What are microneedle patches?

Microneedle patches use tiny needles that painlessly penetrate the skin to deliver medication. They offer a needle-free alternative for some peptide therapies and are currently in development.

How long does it take to develop a combination product?

Development typically takes 5 to 8 years from initial concept to market launch. The device design, human factors testing, and regulatory approval process all add time compared to standalone drug development.